Effect of certolizumab pegol over 96 weeks in patients with psoriatic arthritis with and without prior antitumour necrosis factor exposure

OBJECTIVE: Previous reports of RAPID-PsA (NCT01087788) demonstrated efficacy and safety of certolizumab pegol (CZP) over 24 weeks in patients with psoriatic arthritis (PsA), including patients with prior antitumour necrosis factor (TNF) therapy. We report efficacy and safety data from a 96-week data...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:RMD Open
Main Authors: Mease, P, Deodhar, A, Fleischmann, R, Wollenhaupt, J, Gladman, D, Leszczyński, P, Vitek, P, Turkiewicz, A, Khraishi, M, FitzGerald, O, Landewé, R, de Longueville, M, Hoepken, B, Peterson, L, van der Heijde, D
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2015
Assuntos:
Psoriatic Arthritis
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4612702/
https://ncbi.nlm.nih.gov/pubmed/26509074
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/rmdopen-2015-000119
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados